RECRUITING Phase 2 ClinicalTrials.gov

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Sponsor: UNICANCER • ClinicalTrials.gov ID: NCT07661927

Registry updated: 2026-10-05

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse. It will also evaluate the prognosis of these participants compared to participants who received standard treatment with hormone therapy in another study, estimate the risk of specific recurrence, cardiovascular and bone health, and participants' quality of life. All participants will have undergone surgery and possibly radiation therapy, but unlike standard care, they will not receive hormone therapy afterward. Participants will be enrolled for two years and followed for up to five years after the last participant is enrolled in the trial to monitor for long-term cancer recurrence.

Interventions

Removing Endocrine Therapy (Drug)
The standard of care endocrine therapy (Tamoxifene, Letrozole, Anastrozole or Exemestane) will not be received by the participant during the study.

Eligibility criteria

Inclusion Criteria: * Postmenopausal (underwent bilateral oophorectomy or non-chemo induced amenorrhea for 12 or more months) female participant ≥60 years of age. * New diagnosis of invasive carcinoma of the breast (ductal, tubular or mucinous) with primary tumor ≤1 cm on microscopic exam with no evidence of nodal or distant metastatic disease. * Contralateral breast described as BI-RADS (Breast Imaging-Reporting And Data System) 1 or 2 in diagnostic imaging. * Negative axillary node involvement by sentinel node biopsy or axillary node dissection (pN0) or Clinically negative axillary node involvement (cN0) after mandatory ultrasound exploration without surgical exploration of the axilla if Breast Conservative Surgery (BCS) was performed. * Estrogen Receptor (ER) positive (≥ 50%) and Progesterone Receptor(PR) positive (\> 20%), Ki67 low (≤15%) and HER2 negative (IHC or In Situ Hybridization approach) according to ASCO (American Society of Clinical Oncology) criteria. * Histological grade scored on the invasive component, 1 or 2 if pT1a or grade 1 if pT1b. * Treated by mastectomy or BCS with microscopically clear resection margins defined as "no-ink on tumor" or ≥1 mm for invasive and non-invasive disease or no residual disease on re-excision. * If BCS was performed, participants must have received or have scheduled adjuvant local radiotherapy (RT) within 3 months after surgery * No indication of adjuvant chemotherapy. * The participant is willing and able to comply with the protocol for the duration of the study, including scheduled visits, treatment strategy, laboratory tests and other study procedures. * Participants must be affiliated with a Social Security System (or equivalent). * The participant must have signed a written informed consent form before any trial-specific procedures. When the participant is physically unable to give written consent, an impartial witness of her choice, independent from the investigator or the sponsor, can confirm the participant's consent in writing. Exclusion Criteria: * Have received any neo-adjuvant treatment, including hormone therapy and chemotherapy. * Have received or are eligible for adjuvant chemotherapy. * Absolute contraindication for RT in case of BCS or patients who were treated with partial breast irradiation. * Have been treated with mastectomy and with adjuvant radiotherapy received or scheduled. * Invasive lobular breast cancer. * Bilateral breast cancer or history of other invasive ipsi- or contralateral breast cancer. * Multifocal or multicentric disease. * Disease limited to microinvasion only (\< 1 mm). * Evidence of lymphovascular invasion. * History of non-breast cancer malignancies if not disease-free for \> 5 years and considered low risk of recurrence except for treated carcinoma in situ of the cervix, endometrium or colon, melanoma in situ and basal or squamous cell carcinoma of the skin. * Non-malignant severe disease associated with a life expectancy \< 10 years. * Women with BRCA1, BRCA2 or other high-risk breast cancer predisposing deleterious germline mutations. * Enrolled in another therapeutic study within 30 days prior to inclusion. * Unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons. * Persons deprived of their liberty or under protective custody or guardianship.

Conditions

Breast Cancer (Early Breast Cancer)

Locations

Ico Angers — Angers, France
Sainte Catherine, Institut du Cancer Avignon-Provence — Avignon, France
CH Aunay-Bayeux — Bayeux, France
CHCB — Bayonne, France
Clinique Tivoli — Bordeaux, France
Institut Bergonié — Bordeaux, France
CH Boulogne sur mer — Boulogne-sur-Mer, France
Clinique Pasteur Lanroze — Brest, France
CH de Bligny — Briis-sous-Forges, France
Centre Francois Baclesse — Caen, France
Pole Sante Leonard de Vinci- Roc37 — Chambray-lès-Tours, France
Centre Jean Perrin — Clermont-Ferrand, France
Centre Leonard de Vinci — Dechy, France
Centre Georges François Leclerc — Dijon, France
CH Annecy Genevois — Épagny, France
CHD Vendée — La Roche-sur-Yon, France
Centre Guillaume le Conquérant — Le Havre, France
Centre Oscar Lambret — Lille, France
CHU de Limoges — Limoges, France
Groupe Hospitalier Bretagne Sud — Lorient, France
Centre Léon Bérard — Lyon, France
Hôpital privé Jean Mermoz — Lyon, France
Hôpital Privé Clairval — Marseille, France
Institut Paoli-Calmettes — Marseille, France
CHI de Mont-de-Marsan — Mont-de-Marsan, France
Centre Antoine Lacassagne — Nice, France
CHU Orleans — Orléans, France
CHP Sainte Marie — Osny, France
Groupe Hospitalier Paris Saint Joseph — Paris, France
Institut Curie — Paris, France
Centre Eugène Marquis — Rennes, France
Centre Henri Becquerel — Rouen, France
Institut Curie — Saint-Cloud, France
Ico Saint Herblain — Saint-Herblain, France
CHU de Saint Etienne — Saint-Priest-en-Jarez, France
Centre de lutte contre le cancer - Paul Strauss — Strasbourg, France
Hôpitaux du Léman — Thonon-les-Bains, France
IUCT-Oncopole — Toulouse, France
CHU Tours — Tours, France
Institut de Cancérologie de Lorraine — Vandœuvre-lès-Nancy, France
Groupe UNEOS-Hôpital Robert Schuman — Vantoux, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment